Monte Rosa Therapeutics FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Monte Rosa Therapeutics (GLUE) as of Sep 28, 2026 is 71.19 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -52.28 % — a change of -236.17% (higher).
Get this data via API
Financial Data API
FCF Conversion
71.19 %
YoY
-236.17%
Last updated:
The Monte Rosa Therapeutics FCF Conversion history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Conversion | YoY |
|---|---|---|
| 71.19 % | -236.17% | |
| -52.28 % | -212.60% | |
| 46.43 % | -52.19% | |
| 97.12 % | +3.96% | |
| 93.42 % | +26.77% | |
| 73.70 % | -21.83% | |
| 94.27 % | — |
Monte Rosa Therapeutics Stock analysis
Frequently Asked Questions about Monte Rosa Therapeutics stock
FCF Conversion Rate (FCF/EBITDA) of Monte Rosa Therapeutics is 71.19 % in 2026.
FCF Conversion Rate (FCF/EBITDA) of Monte Rosa Therapeutics changed from -52.28 % to 71.19 %, representing a -236.17% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.
FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.
A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Monte Rosa Therapeutics with sector peers and the industry average to assess whether it is attractive.
To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).
Cash Flow — Monte Rosa Therapeutics
All Key Metrics — Monte Rosa Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth